Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 1:28 AM ET

Pharmaceuticals

Company Overview of Santarus, Inc.

Company Overview

Santarus, Inc., a specialty biopharmaceutical company, focuses on acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company offers UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis; and ZEGERID (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders. It also provides GLUMETZA (metformin hydrochloride extended release tablets) and CYCLOSET (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; ...

3611 Valley Centre Drive

Suite 400

San Diego, CA 92130

United States

Founded in 1996

290 Employees

Phone:

858-314-5700

Fax:

858-314-5701

Key Executives for Santarus, Inc.

President and Director
Age: 54
Vice President of Finance & Investor Relations
Age: 61
Vice President and Corporate Controller
Age: 52
Vice President of Commercial Affairs
Age: 56
Vice President of Sales
Age: 54
Compensation as of Fiscal Year 2015.

Santarus, Inc. Key Developments

Santarus, Inc. Announces Consolidated Audited Earnings Results for the Year Ended Dec. 31, 2013

Santarus, Inc. announced consolidated audited earnings results for the year ended Dec. 31, 2013. For the year, the company reported net product revenues of $933,838,000, income from operations of $271,713,000, income before provision for income tax of $212,065,000, net income of $143,034,000 or $2.18 per diluted share, net cash provided by operating activities of $415,855,000, purchases of property and equipment of $6,936,000 compared to the net product revenues of $735,444,000, income from operations of $172,073,000, income before provision for income tax of $111,828,000, net income of $64,246,000 or $1.01 per diluted share, net cash provided by operating activities of $87,592,000, purchases of property and equipment of $5,370,000 for the previous year.

Santarus, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-27-2014 08:30 AM

Santarus, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-27-2014 08:30 AM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Michael D. Step, Senior Vice President of Corporate Development.

Plaintiff Announces Securities Class Action against Santarus

Plaintiffs alleged that Santarus Inc. violated federal securities laws by making material misstatements and/or omissions in materials and statements disseminated in connection with the company's proposed merger with Salix Pharmaceuticals Inc. The plaintiffs specifically allege that Santarus fraudulently failed to disclose key information regarding the proposed merger, including: the process by which the Santarus board of directors came to agree on the proposed transaction: the analysis by the Santarus board's financial advisor on the fairness of the proposed transaction and the process by which the Santarus board decided to proceed with the merger with Salix rather than shopping for competing offers. Class period: July 11, 2013.

Similar Private Companies By Industry

Company Name Region
Emmaus Life Sciences, Inc. United States
ProStrakan, Inc. United States
Blu Caribe, Inc. United States
Corden Pharma Colorado Inc. United States
MiniVax, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Santarus, Inc., please visit www.santarus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.